Therapeutic Human Polyclonals, Inc.

Therapeutic Human Polyclonals, Inc., (THP) was founded as a biotherapeutics company to develop a unique transgenic mammalian platform to create human antibodies. THP was the first company to create transgenic rabbits with a human antibody repertoire for producing both monoclonal and polyclonal antibody therapeutics.

Roche, the world’s largest biotechnology company, completed its acquisition of THP for $56.5 million in March 29, 2007.

Investors

Research Corporation Technologies and SangStat Medical Corp. (acquired by Genzyme Corporation in Cambridge, Mass.)

Inventors/Founders

• Roland Buelow, Ph.D.
• Wim van Schooten, Ph.D.